News

CURE18h
June Blood Cancer Highlights: Top 5 Updates Patients Should Know
June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...
sharewise3d
FDA Extends INCY's Application for Opzelura Label Expansion
Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...
Physician's Weekly5d
Prognostic Value of Non-JAK2 Mutations in Polycythemia Vera
Non-JAK2 mutations, particularly in SRSF2, ASXL1, and IDH2, were independently associated with worse survival outcomes in ...
Agence France-Presse5d
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Israel launches strikes on missile facilities in central Iran: air force Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy ...